11.37
-0.17 (-1.47%)
| Previous Close | 11.54 |
| Open | 11.52 |
| Volume | 5,709,285 |
| Avg. Volume (3M) | 6,182,134 |
| Market Cap | 8,408,365,056 |
| Price / Earnings (TTM) | 1.98 |
| Price / Sales | 59.25 |
| Price / Book | 1.52 |
| 52 Weeks Range | |
| Earnings Date | 11 Nov 2024 - 15 Nov 2024 |
| Profit Margin | 2,991.76% |
| Operating Margin (TTM) | -402.44% |
| Diluted EPS (TTM) | 5.73 |
| Quarterly Revenue Growth (YOY) | 155.00% |
| Total Debt/Equity (MRQ) | 6.43% |
| Current Ratio (MRQ) | 27.91 |
| Return on Assets (TTM) | -15.03% |
| Return on Equity (TTM) | 127.71% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Roivant Sciences Ltd. | Mixed | Bullish |
Stockmoo Score
| Analyst Consensus | 4.0 |
| Insider Activity | -3.5 |
| Price Volatility | 1.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -0.5 |
| Average | -0.30 |
|
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Mid Growth |
| % Held by Insiders | 29.15% |
| % Held by Institutions | 74.89% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Qvt Financial Lp | 30 Jun 2024 | 66,719,779 |
| Anchorage Capital Group, L.L.C. | 30 Jun 2024 | 4,832,642 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 22.00 (Piper Sandler, 93.49%) | Buy |
| Median | 18.00 (58.31%) | |
| Low | 12.50 (B of A Securities, 9.94%) | Hold |
| Average | 17.50 (53.91%) | |
| Total | 2 Buy, 1 Hold | |
| Avg. Price @ Call | 11.85 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 19 Sep 2024 | 18.00 (58.31%) | Buy | 11.92 |
| 11 Sep 2024 | 18.00 (58.31%) | Buy | 12.38 | |
| B of A Securities | 11 Sep 2024 | 12.50 (9.94%) | Hold | 12.38 |
| Piper Sandler | 10 Jul 2024 | 22.00 (93.49%) | Buy | 11.25 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| GOLD DANIEL ALLEN | - | 11.57 | -876,000 | -10,135,320 |
| PULIK RICHARD | - | 11.48 | -2,340 | -26,863 |
| QVT FINANCIAL LP | - | 11.57 | -876,000 | -10,135,320 |
| Aggregate Net Quantity | -1,754,340 | |||
| Aggregate Net Value ($) | -20,297,503 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 11.54 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| PULIK RICHARD | Officer | 28 Sep 2024 | Disposed (-) | 2,340 | 11.48 | 26,863 |
| GOLD DANIEL ALLEN | Director | 26 Sep 2024 | Sell (-) | 876,000 | 11.57 | 10,135,320 |
| QVT FINANCIAL LP | 26 Sep 2024 | Sell (-) | 876,000 | 11.57 | 10,135,320 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |